Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$115.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc's VPII Escrow Corp Announces Offering Of $1,600 million 6.75% Senior Notes-Form 8-K


Friday, 12 Jul 2013 11:19am EDT 

Valeant Pharmaceuticals International Inc reported in its Form 8-K that on July 12, 2013, VPII Escrow Corp. (the Issuer), a newly formed wholly owned subsidiary of Valeant Pharmaceuticals International Inc. (Parent), completed its previously announced offering (the Notes Offering) of $1,600 million aggregate principal amount of its 6.75% Senior Notes due 2018 and $1,625 million aggregate principal amount of its 7.50% Senior Notes due 2021. The net proceeds of the Notes Offering are expected to be used, together with borrowings under Parent’s credit agreement and the net proceeds of Parent’s equity offering to fund (i) the Merger consideration; (ii) Bausch & Lomb’s obligation to repay all outstanding loans under its existing credit facilities; (iii) Bausch & Lomb’s tender offer for or defeasance or irrevocable call for redemption and deposit of cash to effect such defeasance or redemption of Bausch & Lomb’s 9.875% Senior Notes due 2015; and (iv) certain transaction expenses. 

Company Quote

120.12
3.13 +2.68%
15 Apr 2014